Lilly's Keflex patent
Executive Summary
Lilly plans to appeal a New Jersey Federal Court decision that found scope of Lilly's Keflex (cephalexin) patent was not as broad as the company maintained. Lilly filed a patent infringement suit against Vitarine in February. Lilly says the patent in litigation relates to a dense crystalline form of cephalexin, and maintains that the patent does not expire until 1989. The patent covering the cephalexin molecule expired in April.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.